{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:25:41Z","timestamp":1786955141704,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>\n                    Myeloid sarcoma (MS) is a tumor mass involving any extramedullary site composed of myeloid-lineage blasts with myeloid, myelomonocytic, or monocytic differentiation. Distinguishing MS from malignant histiocytic neoplasms (MHNs) is diagnostically challenging due to morphologic and immunophenotypic overlap, particularly for MS with monocytic differentiation, which can mimic MHNs, especially the subtypes of histiocytic sarcoma and interdigitating dendritic cell sarcoma, leading to potential misdiagnosis and inappropriate management. Cyclin D1 overexpression is implicated in MHNs, but its utility in differentiating these entities has not been systematically characterized. We evaluated cyclin D1 immunostaining in 43 MS cases and 30 MHNs. The median age at MS diagnosis was 59 years (range: 0.1 to 90), while the median age at MHN diagnosis was 62 years (range: 9 to 90), with heterogeneous sites of involvement. Cyclin D1 evaluation showed 100% MHNs with strong cyclin D1 positivity in \u226550% tumor cells, compared with 7% MS with weak-to-intermediate positivity in a minor subset of tumor cells. Additional immunohistochemical evaluation showed no difference in PU.1 expression in MHNs (93%) versus MS (84%) but demonstrated a higher proportion of OCT2-positivity in MHNs over MS (52% vs. 23%,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    &lt;0.05). Our study demonstrates a high sensitivity (100%) and specificity (93%) in utilizing cyclin D1 to distinguish MHNs (mature phenotype) from MS (immature phenotype) in diagnostic practice. It is particularly valuable in challenging scenarios of MS with the absence of immature\/myeloid lineage-defining markers (MPO, CD34, or CD117) and provides a cost-effective tool to resolve this diagnostic pitfall, ensuring an accurate subclassification.\n                  <\/jats:p>","DOI":"10.1097\/pas.0000000000002570","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T09:00:10Z","timestamp":1781514010000},"page":"1067-1075","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Absent Cyclin D1 Expression in Myeloid Sarcomas Distinguishes From Malignant Histiocytic Neoplasms"],"prefix":"10.1097","volume":"50","author":[{"given":"Alyssa M.","family":"Lee","sequence":"first","affiliation":[{"name":"Division of Laboratory Medicine\u2014Hematopathology Section, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Seth","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne","family":"Tam","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuyan","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jithma P.","family":"Abeykoon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongni","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"King","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaaren K.","family":"Reichard","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Goyal","sequence":"additional","affiliation":[{"name":"Division of Hematology-Medical Oncology, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana M.","family":"Morlote","sequence":"additional","affiliation":[{"name":"Division of Laboratory Medicine\u2014Hematopathology Section, University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Rech","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4503-440X","authenticated-orcid":false,"given":"Aishwarya","family":"Ravindran","sequence":"additional","affiliation":[{"name":"Division of Laboratory Medicine\u2014Hematopathology Section, University of Alabama at Birmingham, Birmingham, AL"},{"name":"Department of Laboratory Medicine and Pathology, Division of Hematopathology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On Behalf of the Histio-Care Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"R1-20260817","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1007\/s00277-023-05288-1","article-title":"Myeloid sarcoma: more and less than a distinct entity","volume":"102","author":"Loscocco","year":"2023","journal-title":"Ann Hematol"},{"key":"R3-20260817","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.prp.2016.06.014","article-title":"Clinicopathological features of myeloid sarcoma: report of 39 cases and literature review","volume":"212","author":"Wang","year":"2016","journal-title":"Pathol Res Pract"},{"key":"R4-20260817","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"R5-20260817","doi-asserted-by":"crossref","first-page":"100268","DOI":"10.1016\/j.modpat.2023.100268","article-title":"Malignant histiocytosis comprises a phenotypic spectrum that parallels the lineage differentiation of monocytes, macrophages, dendritic Cells, and Langerhans cells","volume":"36","author":"Ravindran","year":"2023","journal-title":"Mod Pathol"},{"key":"R6-20260817","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"key":"R7-20260817","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/ajh.27263","article-title":"Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis","volume":"99","author":"Ruan","year":"2024","journal-title":"Am J Hematol"},{"key":"R8-20260817","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/PAS.0000000000002506","article-title":"Cyclin D1 overexpression with cytoplasmic localization distinguishes Erdheim-Chester disease from reactive histiocytic infiltrates","volume":"50","author":"Oskarsdottir","year":"2026","journal-title":"Am J Surg Pathol"},{"key":"R9-20260817","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ajcp\/aqad047","article-title":"How I diagnose Rosai-Dorfman disease","volume":"160","author":"Ravindran","year":"2023","journal-title":"Am J Clin Pathol"},{"key":"R10-20260817","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.3324\/haematol.2024.286479","article-title":"Histiocyte Society blueprint for non-Langerhans cell histiocytosis research: unraveling complex diseases through collaboration","volume":"110","author":"Hershkovitz-Rokah","year":"2025","journal-title":"Haematologica"},{"key":"R11-20260817","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"R12-20260817","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.neo.2018.09.007","article-title":"S100 proteins in acute myeloid leukemia","volume":"20","author":"Brenner","year":"2018","journal-title":"Neoplasia"},{"key":"R13-20260817","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/jcp.42.2.188","article-title":"Granulocytic sarcoma: misleading immunohistological staining with MT1 and S100 protein antibodies","volume":"42","author":"Elliott","year":"1989","journal-title":"J Clin Pathol"},{"key":"R14-20260817","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1182\/blood-2017-02-767566","article-title":"S100 proteins in AML: differentiation and beyond","volume":"129","author":"Tamburini","year":"2017","journal-title":"Blood"},{"key":"R15-20260817","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3389\/fimmu.2019.00228","article-title":"Mechanisms of action of hematopoietic transcription factor PU.1 in initiation of T-cell development","volume":"10","author":"Rothenberg","year":"2019","journal-title":"Front Immunol"},{"key":"R16-20260817","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/his.14909","article-title":"PU.1 is a useful nuclear marker to distinguish between histiocytosis and histiocyte-rich tumours","volume":"83","author":"Ungureanu","year":"2023","journal-title":"Histopathology"},{"key":"R17-20260817","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1309\/UJUL60UPUP3YJE93","article-title":"Expression of the B cell-associated transcription factors PAX5, OCT-2, and BOB.1 in acute myeloid leukemia: associations with B-cell antigen expression and myelomonocytic maturation","volume":"126","author":"Gibson","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"R18-20260817","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/ajcp\/aqac119","article-title":"Strong coexpression of transcription factors PU.1 and Oct-2 in Rosai-Dorfman disease","volume":"158","author":"Kiruthiga","year":"2022","journal-title":"Am J Clin Pathol"},{"key":"R19-20260817","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/PAS.0000000000001617","article-title":"Rosai-Dorfman disease displays a unique monocyte-macrophage phenotype characterized by expression of OCT2","volume":"45","author":"Ravindran","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"R20-20260817","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00428-023-03508-7","article-title":"OCT2 expression in histiocytoses","volume":"483","author":"Ungureanu","year":"2023","journal-title":"Virchows Arch"},{"key":"R21-20260817","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/DAD.0000000000001250","article-title":"CyclinD1 Is useful to differentiate Langerhans cell histiocytosis from reactive Langerhans cells","volume":"41","author":"Chatterjee","year":"2019","journal-title":"Am J Dermatopathol"},{"key":"R22-20260817","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.cub.2006.04.044","article-title":"Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression","volume":"16","author":"Yamamoto","year":"2006","journal-title":"Curr Biol"},{"key":"R23-20260817","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.clml.2017.02.027","article-title":"Myeloid sarcoma: presentation, diagnosis, and treatment","volume":"17","author":"Almond","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R24-20260817","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/MOH.0000000000000571","article-title":"Myeloid sarcoma","volume":"27","author":"Shahin","year":"2020","journal-title":"Curr Opin Hematol"},{"key":"R25-20260817","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1002\/1878-0261.70085","article-title":"Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation","volume":"19","author":"Cardona-Benavides","year":"2025","journal-title":"Mol Oncol"},{"key":"R26-20260817","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1016\/j.apsb.2024.03.013","article-title":"Disruption of cyclin D1 degradation leads to the development of mantle cell lymphoma","volume":"14","author":"Lu","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"R27-20260817","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.3390\/jcm13206154","article-title":"Myeloid sarcoma: novel advances regarding molecular pathogenesis, presentation and therapeutic options","volume":"13","author":"Diamantidis","year":"2024","journal-title":"J Clin Med"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:00:22Z","timestamp":1786953622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PAS.0000000000002570"}},"subtitle":["When Morphologic Ambiguity is Deceptive"],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002570","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"2026-03-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}